Login / Signup

Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy.

Maria Laura FeltriNadav I WeinstockJacob FavretNarayan DhimalLawrence WrabetzDaesung Shin
Published in: Glia (2021)
Globoid cell leukodystrophy (GLD), also known as Krabbe disease, is a lysosomal storage disorder causing extensive demyelination in the central and peripheral nervous systems. GLD is caused by loss-of-function mutations in the lysosomal hydrolase, galactosylceramidase (GALC), which catabolizes the myelin sphingolipid galactosylceramide. The pathophysiology of GLD is complex and reflects the expression of GALC in a number of glial and neural cell types in both the central and peripheral nervous systems (CNS and PNS), as well as leukocytes and kidney in the periphery. Over the years, GLD has garnered a wide range of scientific and medical interests, especially as a model system to study gene therapy and novel preclinical therapeutic approaches to treat the spontaneous murine model for GLD. Here, we review recent findings in the field of Krabbe disease, with particular emphasis on novel aspects of GALC physiology, GLD pathophysiology, and therapeutic strategies.
Keyphrases
  • cell therapy
  • single cell
  • gene therapy
  • healthcare
  • blood brain barrier
  • peripheral blood
  • bone marrow